Several editions of the World Health Organization (WHO) classifications of lympho‐
hemopoietic neoplasms in 2001, 2008, and 2016 served as the international standard for …

TP53 is a key tumor suppressor gene with protean functions associated with preservation of
genomic balance, including regulation of cellular senescence, apoptotic pathways …

PURPOSE TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML) have very poor outcome irrespective of the treatment received, including …

TP53 mutations are associated with poor outcomes in acute myeloid leukemia (AML). The
prognostic impact of mutant TP53 (TP53 mut) variant allelic frequency (VAF) is not well …

Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and
myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact assessment of …

Somatic TP53 mutations and 17p deletions with genomic loss of TP53 occur in 37% to 46%
of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary …

PURPOSE Allogeneic hematopoietic cell transplantation (HCT) in patients with
myelodysplastic syndrome (MDS) improves overall survival (OS). We evaluated the impact …

Background Venetoclax (VEN) in combination with a hypomethylating agent (HMA) has
become the standard of care for patients aged> 75 years and for those not eligible for …

BACKGROUND The presence of TP53 mutations is associated with an unfavorable outcome
in patients allografted for acute myeloid leukemia (AML), leading some to question the …

TP53‐altered myelodysplastic syndrome with excess blasts and TP53‐altered acute myeloid
leukemia should be considered under one unifying classification term for their study in …